U.S. Real Estate Stock News

NYSE:PLGO
NYSE:PLGOInsurance

Fidelis Buyback And Bye Law Changes Reframe Capital Return Outlook

Fidelis Insurance Holdings (NYSE:FIHL) has entered into a major share repurchase agreement that ends founding shareholder CVC Falcon Holdings Limited's ownership stake. The company has also approved amendments to its Bye Laws at its latest annual meeting, signaling changes to its governance framework. These decisions mark a meaningful shift in ownership and corporate rules that is relevant for existing and prospective shareholders. Fidelis Insurance Holdings, a specialty insurance and...
NasdaqGM:ODD
NasdaqGM:ODDPersonal Products

Oddity Tech (ODD) Is Down 8.5% After Class Action Over Ad Cost Disclosures - What's Changed

The Gross Law Firm recently announced a class action lawsuit on behalf of Oddity Tech shareholders, alleging the company made materially false and misleading statements about digital advertising costs after an algorithm change by its largest advertising partner increased customer acquisition costs and hurt its business outlook. This legal challenge raises fresh questions about how dependent Oddity’s business model is on a single digital ad ecosystem and the transparency of its cost...
NYSE:PRI
NYSE:PRIInsurance

Primerica Household Budget Index Signals Stable Clients And Supports PRI Valuation

Primerica released its latest Household Budget Index, showing middle-income family finances are stabilizing despite ongoing cost pressures. The HBI has remained above 100 for nine consecutive months, indicating that middle-income households are maintaining improved purchasing power. The data offers a fresh read on consumer resilience, which is closely watched by investors tracking trends in spending and financial health. For investors following Primerica (NYSE:PRI), the new Household Budget...
NasdaqGS:COKE
NasdaqGS:COKEBeverage

Vanguard’s Passive Stake Meets Coca-Cola Consolidated Valuation And Momentum Story

Vanguard Capital Management and Vanguard Portfolio Management have each disclosed beneficial ownership above 5% in Coca-Cola Consolidated. The filings show that a substantial portion of NasdaqGS:COKE shares is now held passively, with no stated intent to influence management or operations. This change adds a large, long term oriented institution to the shareholder register, which may interest both existing and prospective investors. Coca-Cola Consolidated, listed on NasdaqGS:COKE, last...
NYSE:CPT
NYSE:CPTResidential REITs

Camden Property Trust (CPT) Q1 FFO Drop Questions Bullish Sun Belt Apartment Narrative

Camden Property Trust (CPT) opened 2026 with Q1 revenue of US$390.0 million, basic EPS of US$0.40 and net income of US$42.4 million, alongside Funds From Operations of US$122.9 million that many investors watch closely for a residential REIT. Over the past several quarters, revenue has moved from US$387.8 million in Q4 2024 to a range between US$393.1 million and US$399.2 million across 2025, while basic EPS has shifted between US$0.36 and US$1.44 over that same period. Taken together with a...
NYSE:BVN
NYSE:BVNMetals and Mining

Buenaventura Permits And San Gabriel Ramp Up Reframe Earnings Outlook

Compañía de Minas BuenaventuraA (NYSE:BVN) reported multiple operational and permitting milestones in Q1 2026, including the production ramp up at San Gabriel. The company received key stage 1 operating and water use permits for San Gabriel, while Yumpag and El Brocal secured capacity expansion approvals. Gold production, company wide revenue, and profitability all saw significant gains in the quarter, alongside these project advances. For investors watching NYSE:BVN, these updates come...
NasdaqGM:TVTX
NasdaqGM:TVTXBiotechs

Is It Too Late To Consider Travere Therapeutics (TVTX) After Its Strong Share Price Rally?

Wondering whether Travere Therapeutics at around US$44.12 is still offering value or if the easy gains are already behind it? This article unpacks what the current price really implies. The stock has shown strong share price moves, with returns of 8.9% over 7 days, 40.4% over 30 days, 11.6% year to date, 108.6% over 1 year, 162.6% over 3 years and 120.5% over 5 years. This naturally raises questions about both upside potential and risk. Recent headlines around Travere Therapeutics have...